Synergistic Enteral Regimen for Treatment of the Gangliosidoses

Key facts

Sponsor

University of Minnesota

Principal Investigator

Jeanine R. Jarnes, PharmD

University of Minnesota Fairview Hospital

Intervention

miglustat(drug)

Enrollment

16 enrolled

Eligibility

All sexes

Timeline

2015 – 2019

Study locations (1)

• University of Minnesota, Minneapolis, Minnesota, United States

Collaborators

Rare Diseases Clinical Research Network · National Center for Advancing Translational Sciences (NCATS) · National Institute of Neurological Disorders and Stroke (NINDS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Lysosomal Disease Network

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Gangliosidosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07082543
  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
  Azafaros A.G.
• RECRUITINGPHASE1, PHASE2NCT03952637
  A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis
  National Human Genome Research Institute (NHGRI)
• RECRUITINGNCT00668187
  A Natural History Study of the Gangliosidoses
  University of Minnesota

See all trials for Gangliosidosis →